The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1552
ISSUE 1552
July 30, 2018
Drugs for Rheumatoid Arthritis
| The full article is available to subscribers | Subscriber Login |
July 30, 2018 (Issue: 1552)
Disease-modifying antirheumatic drugs (DMARDs)
are used for initial treatment of rheumatoid arthritis
(RA) to achieve clinical remission and prevent
irreversible joint damage (see Table 1). DMARDs
generally do not have an immediate analgesic effect,
but over time they can control symptoms and have
been shown to delay and possibly stop progression
of the disease. Methotrexate (Trexall, and others)
is generally the drug of choice; it can be used for
patients with low, moderate, or high disease activity.
For mild disease, some clinicians prefer to start with
hydroxychloroquine (Plaquenil, and generics) and/or
sulfasalazine (Azulfidine, and others).
... more
- JA Singh et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016; 68:1.
- JR O’Dell et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013; 369:307.
- MF Marmor et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2016; 123:1386.
- N Abdulaziz et al. Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol 2018; 30:249.
- N Alcorn et al. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009; 32:1123.
- Drugs for inflammatory bowel disease. Med Lett Drugs Ther 2018; 60:107.
- Drug interactions from The Medical Letter. Available at: www.secure.medicalletter.org/subDIO. Accessed July 19, 2018.
- KR Reddy et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148:215.
- JS Smolen et al. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis 2014; 73:1811.
- Sarilumab (Kevzara) for rheumatoid arthritis. Med Lett Drugs Ther 2017; 59:134.
- Tocilizumab (Actemra) for rheumatoid arthritis. Med Lett Drugs Ther 2010; 52:47.
- C Gabay et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013; 381:1541.
- M Dougados et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013; 72:43.
- Rituximab (Rituxan) for rheumatoid arthritis. Med Lett Drugs Ther 2006; 48:34.
- SB Cohen et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793.
- Abatacept (Orencia) for rheumatoid arthritis. Med Lett Drugs Ther 2006; 48:17.
- Tofacitinib (Xeljanz) for rheumatoid arthritis. Med Lett Drugs Ther 2013; 55:1.
- EB Lee et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370:2377.
- RF van Vollenhoven et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367:508.
- Baricitinib (Olumiant) for rheumatoid arthritis. Med Lett Drugs Ther 2018; 60:120.
- ML Krause and A Makol. Management of rheumatoid arthritis during pregnancy: challenges and solutions. Open Access Rheumatol 2016; 8:23.
- MF Bakker et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012; 156:329.
- Nonopioid drugs for pain. Med Lett Drugs Ther 2018; 60:24.
- Diclofenac gel for osteoarthritis. Med Lett Drugs Ther 2008; 50:31.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Rheumatoid Arthritis
Article code: 1552a
Electronic, downloadable article - $45
Article code: 1552a
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
